Log in

ASX:MSBMesoblast Stock Price, Forecast & News

A$1.34
-0.12 (-8.19 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
A$1.32
Now: A$1.35
A$1.50
50-Day Range
A$1.10
MA: A$1.98
A$2.92
52-Week Range
A$1.02
Now: A$1.35
A$3.21
Volume4.48 million shs
Average Volume2.19 million shs
Market Capitalization$721.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-96396036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.47 million
Cash FlowA$0.16 per share
Book ValueA$0.94 per share

Profitability

Miscellaneous

Employees81
Market Cap$721.97 million
Next Earnings Date5/29/2020 (Estimated)
OptionableOptionable

Receive MSB News and Ratings via Email

Sign-up to receive the latest news and ratings for MSB and its competitors with MarketBeat's FREE daily newsletter.


Mesoblast (ASX:MSB) Frequently Asked Questions

How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)?

Mesoblast's stock was trading at A$1.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MSB stock has decreased by 25.7% and is now trading at A$1.35. View which stocks have been mosted impacted by Coronavirus.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Mesoblast.

How were Mesoblast's earnings last quarter?

Mesoblast limited (ASX:MSB) announced its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. View Mesoblast's earnings history.

Has Mesoblast been receiving favorable news coverage?

Press coverage about MSB stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMesoblast.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Starpharma (SPL), GENFIT S A/ADR (GNFT), Portola Pharmaceuticals (PTLA), Viking Therapeutics (VKTX), Immutep (IMM) and Evolution Mining (EVN).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

What is Mesoblast's stock symbol?

Mesoblast trades on the ASX under the ticker symbol "MSB."

What is Mesoblast's stock price today?

One share of MSB stock can currently be purchased for approximately A$1.35.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $721.97 million and generates $22.47 million in revenue each year. Mesoblast employs 81 workers across the globe. View additional information about Mesoblast.

What is Mesoblast's official website?

The official website for Mesoblast is http://www.mesoblast.com/.

How can I contact Mesoblast?

Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036.

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel